(Q31900813)

4 July 2017

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets (English)

1 reference

4 July 2017

1 reference

Iravani MM

1

1 reference

4 July 2017

Costa S

2

1 reference

4 July 2017

Jackson MJ

3

1 reference

4 July 2017

Tel BC

4

1 reference

4 July 2017

Cannizzaro C

5

1 reference

4 July 2017

Pearce RK

6

1 reference

4 July 2017

Jenner P

7

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

European Journal of Neuroscience

4 July 2017

1 reference

4 July 2017

13

1 reference

4 July 2017

3

1 reference

4 July 2017

597-608

1 reference

6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor

4 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Aetiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Dopaminergic neurons protected from degeneration by GDNF gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Functional recovery in parkinsonian monkeys treated with GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial-cell-line-derived neurotrophic factor enhances biosynthesis of substance P in striatal neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Success and problems of long-term levodopa therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Rate of cell death in parkinsonism indicates active neuropathological process

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Effects of combined BDNF and GDNF treatment on cultured dopaminergic midbrain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1460-9568.2001.01408.X

10.1046/J.1460-9568.2001.01408.X

21 January 2018

Identifiers

DOI

1 reference

4 July 2017

1 reference